


## Protein kinase D inhibitor 1

Cat. No.:	HY-151372
CAS No.:	2489320-03-6
Molecular Formula:	C <sub>19</sub> H <sub>21</sub> N <sub>7</sub>
Molecular Weight:	347.42
Target:	PKD
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Protein kinase D inhibitor 1 (compound 17m) is a pan-PKD inhibitor, with IC <sub>50</sub> values ranging from 17 to 35 nM. Protein kinase D inhibitor 1 inhibits PKD-dependent cortactin phosphorylation <sup>[1]</sup> .										
<b>IC<sub>50</sub> &amp; Target</b>	PKD3 17 ± 8 nM (IC <sub>50</sub> )	PKD2 35 ± 5 nM (IC <sub>50</sub> )	PKD1 35 ± 10 nM (IC <sub>50</sub> )								
<b>In Vitro</b>	<p>Protein kinase D inhibitor 1 (compound 17m) displays excellent PKD2 inhibition with almost no remaining kinase activity at 1 μM<sup>[1]</sup>.</p> <p>Protein kinase D inhibitor 1 displays only weak antiproliferative activity, and does not significantly affect PANC-1 cell proliferation at a concentration of 5 μM<sup>[1]</sup>.</p> <p>Protein kinase D inhibitor 1 (0-100 μM, 72 h) shows antitumor activity<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>LN-229, Capan-1, DND-41, HL-60, Z-138, NCI-H460, HCT-116, K-562</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited of tumor cell growth of LN-229, Capan-1, DND-41, HL-60, Z-138, NCI-H460, HCT-116, and K-562, with IC<sub>50</sub> values of 80.6 ± 7, 40.7 ± 14.5, 42.7 ± 4.9, 17.9 ± 4.1, 35.3 ± 10.4, &gt;95.8, &gt;100, and &gt;100, respectively.</td> </tr> </table>			Cell Line:	LN-229, Capan-1, DND-41, HL-60, Z-138, NCI-H460, HCT-116, K-562	Concentration:	0-100 μM	Incubation Time:	72 h	Result:	Inhibited of tumor cell growth of LN-229, Capan-1, DND-41, HL-60, Z-138, NCI-H460, HCT-116, and K-562, with IC <sub>50</sub> values of 80.6 ± 7, 40.7 ± 14.5, 42.7 ± 4.9, 17.9 ± 4.1, 35.3 ± 10.4, >95.8, >100, and >100, respectively.
Cell Line:	LN-229, Capan-1, DND-41, HL-60, Z-138, NCI-H460, HCT-116, K-562										
Concentration:	0-100 μM										
Incubation Time:	72 h										
Result:	Inhibited of tumor cell growth of LN-229, Capan-1, DND-41, HL-60, Z-138, NCI-H460, HCT-116, and K-562, with IC <sub>50</sub> values of 80.6 ± 7, 40.7 ± 14.5, 42.7 ± 4.9, 17.9 ± 4.1, 35.3 ± 10.4, >95.8, >100, and >100, respectively.										

### REFERENCES

[1]. Gilles P, et al. Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors. Eur J Med Chem. 2020 Nov 1;205:112638.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA